Table 1.
Summary of included studies
| Studies | Year published | Study period (months) | Medication | Disease | N in drug group | N in placebo group | Metric of FVC change used in meta-analysis | All-cause mortality available |
|---|---|---|---|---|---|---|---|---|
| Richeldi et al. TOMORROW trial | 2011 | 12 | Nintedanib | IPF | 84 | 83 | mls/year | Yes |
| Richeldi et al. INPULSIS trial 1 | 2014 | 12 | Nintedanib | IPF | 309 | 204 | mls/year | Yes |
| Richeldi et al. INPULSIS trial 2 | 2014 | 12 | Nintedanib | IPF | 329 | 219 | mls/year | Yes |
| Flaherty et al. INBUILD trial | 2019 | 12 | Nintedanib | Non-IPF | 206 | 206 | mls/year | Yes |
| Distler et al. NCT 02597933 | 2019 | 12 | Nintedanib | Non-IPF | 288 | 288 | mls/year | Yes |
| Azuma et al. | 2005 | 9 | Pirfenidone | IPF | 73 | 36 | mls over 9 months | No |
| Taniguchi et al. | 2010 | 12 | Pirfenidone | IPF | 108 | 104 | mls/year | No |
| Noble et al. CAPACITY NCT 00287729 | 2011 | 18 | Pirfenidone | IPF | 174 | 174 | % predicted FVC | Yes |
| Noble et al. CAPACITY NCT 00287716 | 2011 | 18 | Pirfenidone | IPF | 171 | 173 | % predicted FVC | Yes |
| Huang et al. | 2015 | 11 | Pirfenidone | IPF | 38 | 38 | mls over study period | Yes |
| King et al. ASCEND trial | 2014 | 12 | Pirfenidone | IPF | 278 | 277 | Slope of fall in FVC mls | Yes |
| Maher et al. | 2020 | 6 | Pirfenidone | Non-IPF | 118 | 119 | mls FVC over study period | Yes |
| Behr et al.s | 2021 | 11 | Pirfenidone | Non-IPF | 35 | 32 | % predicted FVC | Yes |